AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ATAI · NASDAQ · Biotechnology

Atai Beckley

Develops clinical-stage psychiatric candidates for difficult-to-treat mental-health conditions.

$7.29

After-hours close0.00 (0.00%)

At close$7.29(−0.82%)

Something off on this page? Send us feedback.

Profile

Atai Beckley N.VATAIHealth Care

Develops a clinical-stage portfolio of interventional psychiatric candidates, including BPL-003, VLS-01 and EMP-01. The business was formed by atai and Beckley Psytech and is not reliant on commercial-product revenue.

Develops interventional psychiatric candidates for difficult-to-treat mental-health conditions. The clinical-stage biotechnology business advances BPL-003, VLS-01 and EMP-01, as well as an earlier-stage 5-HT2A program. The portfolio spans programs at different stages of development. Rather than selling a commercialized product, it develops a portfolio of candidate therapies.

The current company was formed through the combination of atai and Beckley Psytech, connecting atai’s prior platform model with Beckley’s programs. Its work is shaped by clinical development across the portfolio. An announced acquisition by Eli Lilly remains pending stockholder and regulatory approvals and customary closing conditions.

Company facts

CEOSrinivas Rao, M.D., Ph.D.

ListedJun 18, 2021

ExchangeNASDAQ

HeadquartersNew York, NY

CountryNetherlands

Employees99

CIK0002081043

ISINUS04650F1012

Key statistics

Market cap$2.70B

EPS (ttm)−$2.90

P/E (ttm)−2.51

ROE-353.2%

P/B14.91

P/S602.94

Dividend yield—

Beta1.32vs XLV 0.72

Year to date +88.4% · Average volume (30d) 8.9M

Analysts

Price target, next 12 months$7.50+2.9%Median of 8 analysts · vs the Aug 28 close

ConsensusHold0 of 8 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $7.29

High$8.00+9.7%

Median$7.50+2.9%

Low$7.45+2.2%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Aug 17, 2026	Oppenheimer	Downgrade	Outperform	Perform
Aug 12, 2026	Deutsche Bank	Downgrade	Buy	Hold	$12	$8
Jul 20, 2026	H.C. Wainwright	Downgrade	Buy	Neutral		$7.50
Jul 20, 2026	Berenberg Bank	Target				$7.45
Jul 20, 2026	HC Wainwright & Co.	Downgrade	Buy	Neutral

Earnings

EPS

Estimate−$0.12

ReportedDue Nov 12, 2026

Revenue

Estimate$300.0K

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 11, 2026Q2 FY26	−$0.11	−$0.09	+15.6%	$940.8K	$1.7M	+81.1%	−0.55%
May 12, 2026Q1 FY26	−$0.11	−$0.08	+27.3%	$217.1K	$954.0K	+339.4%	+2.17%
Mar 6, 2026Q4 FY25	−$0.12	−$0.05	+58.3%	$300.0K	$1.1M	+255.3%	+14.75%
Nov 12, 2025Q3 FY25	−$0.12	−$0.28	−133.3%	$229.2K	$749.0K	+226.8%	−4.62%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$1.6M	$719.0K	$749.0K	$1.1M	$954.0K	$1.7M
Gross profit	$1.3M	$492.0K	$516.0K	$1.1M	$787.0K	$1.5M
Operating income	−$20.4M	−$25.3M	−$28.4M	−$43.0M	−$30.9M	−$44.1M
Net income	−$26.4M	−$27.7M	−$61.1M	−$544.8M	−$29.8M	−$32.5M
Diluted EPS	−$0.15	−$0.14	−$0.28	−$2.45	−$0.08	−$0.09
Gross margin	86.1%	68.4%	68.9%	100.0%	82.5%	87.4%
Operating margin	-1,310.0%	-3,515.0%	-3,796.5%	-4,032.1%	-3,239.1%	-2,590.4%

Fiscal years (4-quarter sums)FY21 $20.4M · FY22 $232.0K · FY23 $314.0K · FY24 $308.0K · FY25 $4.1M

Revenue by product · FY24

Research And Development Services$300.0K · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $225.8M · Total debt $4.3M · Total assets $264.8M · Shareholders' equity $176.4M

Dividends

No dividends on record.

Ownership

Institutions 37.12%137.31M sharesInsiders 2.26%8.38M sharesOther 60.62%224.26M shares

Shares outstanding 369.95M · Float 201.02M · 54.3% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Apeiron Investment Group Ltd. · 10 percent owner	53.41M	14.44%	Form 4	Oct 2, 2025
BlackRock, Inc.	25.57M	6.91%	13F	Aug 7, 2026
Deep Track Capital, LP	14.42M	3.90%	13F	Aug 14, 2026
Vanguard Capital Management LLC	11.75M	3.18%	13F	Aug 13, 2026
State Street Corp	8.29M	2.24%	13F	Aug 7, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.